Eosinophils
Eosinophils are granulocytes — a category of white blood cell that, like Mast Cells, store pre-formed chemical mediators in granules and release them when activated. They’re most associated with parasitic infection defense and allergic disease, but their relationship with mast cells is bidirectional and clinically important in MCAS.
What Eosinophils Are
Named for their affinity for eosin dye — they stain bright pink/orange under microscopy, which makes them easy to identify in tissue samples. Produced in bone marrow, they mature and enter circulation, then migrate into tissues when recruited by inflammatory signals.
Unlike Mast Cells, eosinophils are not permanent tissue residents — they’re recruited to sites of inflammation and can be found in abnormally high numbers in tissues during allergic or inflammatory disease.
Normal peripheral blood eosinophil count: 100–500 cells/µL. Elevated counts (eosinophilia) signal ongoing allergic, inflammatory, or parasitic disease.
What Eosinophils Release
Like mast cells, eosinophils store mediators in granules for rapid release. Their primary granule proteins are cytotoxic — evolved for killing parasites:
Major Basic Protein (MBP) — Disrupts cell membranes. Toxic to parasites, but also to bronchial epithelium, causing airway damage in asthma. Can directly trigger mast cell degranulation. This is a key bidirectional link.
Eosinophil Cationic Protein (ECP) — Ribonuclease with cytotoxic and neurotoxic effects. Damages nerve tissue and epithelium. Used as a biomarker for eosinophil activation.
Eosinophil-Derived Neurotoxin (EDN) — Another ribonuclease. Contributes to neurological inflammation.
Eosinophil Peroxidase (EPO) — Generates reactive oxygen species (ROS), oxidative damage to surrounding tissue.
Beyond granule proteins, eosinophils also produce:
- Leukotrienes (especially LTC4) — same bronchoconstricting pathway as mast cells
- Prostaglandins — overlapping with the mast cell lipid mediator cascade
- Cytokines — IL-4, IL-5, IL-13, TGF-β, TNF-α
- Platelet-activating factor (PAF)
The overlap with mast cell mediator output is significant — activated eosinophils can produce many of the same downstream effects as activated mast cells.
The Mast Cell–Eosinophil Relationship
These two cell types are not independent — they actively regulate each other.
Mast Cells Recruit Eosinophils
During Degranulation, mast cells release:
- IL-5 — the primary eosinophil survival and activation cytokine
- Eotaxin (CCL11) — a potent chemokine that specifically recruits eosinophils to the site
- IL-4 and IL-13 — promote eosinophil survival and tissue infiltration
- PAF — activates eosinophils directly
So when mast cells fire, one downstream consequence is recruitment of eosinophils to the same tissue. The mast cell lays the groundwork; eosinophils arrive as reinforcements.
Eosinophils Activate Mast Cells
Major Basic Protein (MBP) — released by eosinophils — directly triggers mast cell degranulation. This is the key reciprocal link. MBP binds to heparin-proteoglycan complexes on the mast cell surface and activates the cell via a non-IgE mechanism.
Eosinophils also produce NGF (nerve growth factor) and substance P, both of which activate mast cells through Non-IgE Activation Pathways.
The result: mast cell activation → eosinophil recruitment → eosinophil activation → more mast cell activation. Another amplification loop layered on top of the ones already present in MCAS.
Shared Tissue Residency in Allergic Disease
In allergic airway disease and eosinophilic GI disorders, mast cells and eosinophils co-localize in affected tissues and appear to function as a coordinated unit. They’re found together, they activate each other, and they produce overlapping mediators that compound the inflammatory signal.
Eosinophils and MCAS Specifically
The relationship is underrecognized in clinical MCAS management. Key points:
Eosinophilic GI disorders (EoE, EoG, EoC) overlap with MCAS. Eosinophilic esophagitis, eosinophilic gastritis, and eosinophilic colitis involve pathological eosinophil infiltration of GI tissue. These conditions occur at higher rates in MCAS patients, and both involve mast cells as well. In biopsy samples from these patients, elevated mast cells and eosinophils are found together — not coincidentally.
Peripheral eosinophilia is sometimes present in MCAS. Not always, and not always dramatically elevated, but some MCAS patients have mildly elevated peripheral eosinophil counts. This is a clue that deserves investigation rather than dismissal.
Eosinophils contribute to the delayed wave. The immediate mast cell degranulation phase produces rapid-onset symptoms. Eosinophil recruitment over the following hours contributes to the delayed, prolonged inflammatory component. The biphasic pattern of symptoms in some MCAS reactions — acute flare, apparent improvement, then second wave — may partially reflect this eosinophil recruitment timeline.
Shared trigger pathways. Eosinophils have IgE receptors (though lower-affinity than mast cells) and can be activated by allergens independently. In a sensitized patient, both cell types may be responding to the same food or environmental trigger simultaneously through parallel pathways.
Treatment Implications
Most MCAS treatment focuses on mast cell mediators. When eosinophils are significantly involved, the picture is more complex.
Montelukast — blocks CysLT1 receptors, relevant to both mast cell and eosinophil leukotriene output. One of the reasons montelukast helps in MCAS even without an obvious leukotriene-dominant picture.
Cromolyn sodium — primarily a mast cell stabilizer but some evidence for eosinophil activity suppression as well.
Dupilumab (Dupixent) — IL-4/IL-13 receptor blocker, approved for eosinophilic esophagitis and atopic dermatitis. Blocks two cytokines that are central to both mast cell and eosinophil activity. Relevant for MCAS/EoE overlap patients, though not approved for MCAS.
Mepolizumab, benralizumab — anti-IL-5 and anti-IL-5 receptor antibodies. Approved for severe eosinophilic asthma, sometimes used in hypereosinophilic syndrome. Not MCAS-specific but potentially relevant in MCAS with significant eosinophilia.
GLP-1RAs — GLP-1 receptors are expressed on eosinophils. The anti-inflammatory effects of GLP-1 agonists include reduction of eosinophil activation markers and Th2 cytokine production in studies of asthma. This may be part of why GLP-1RAs show broad benefit in MCAS — they’re dampening both cell types simultaneously.
Differentiating Eosinophil-Dominant vs Mast Cell-Dominant Disease
Clinically, this matters for treatment selection:
| Feature | More Mast Cell | More Eosinophil |
|---|---|---|
| Onset | Rapid (seconds–minutes) | Slower (hours) |
| Tryptase elevation | Yes (if full degranulation) | No |
| Peripheral eosinophilia | Not typical | Sometimes present |
| Food texture triggers | Less typical | Common in EoE/EoG |
| Tissue biopsy | Elevated mast cells | Elevated eosinophils |
| Urinary PGD2 metabolites | Elevated | Less specific |
| Response to H1/H2 | Often partial | Often incomplete |
In practice, many patients have both. The distinction matters most when standard MCAS treatment is producing incomplete response — the eosinophil component may not be adequately addressed.
Related Notes
- Mast Cell Mediators — overlapping mediator profiles
- Cytokines — IL-5 as the key eosinophil recruitment signal from mast cells
- Leukotrienes — shared pathway output
- Non-IgE Activation Pathways — MBP as a direct mast cell activator
- Montelukast — hits both mast cell and eosinophil leukotriene output
- GLP-1 Receptor Agonists and Mast Cells — dampens both cell types
- The Trifecta — MCAS, POTS, and EDS — eosinophilic GI disorders as additional comorbidity in this population